Downloads: 18

Files in This Item:
File Description SizeFormat 
cancers11121891.pdf3.1 MBAdobe PDFView/Open
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNishiuchi, Ayaen
dc.contributor.authorHisamori, Shigeoen
dc.contributor.authorSakaguchi, Masazumien
dc.contributor.authorFukuyama, Keitaen
dc.contributor.authorHoshino, Nobuakien
dc.contributor.authorItatani, Yoshiroen
dc.contributor.authorHonma, Shusakuen
dc.contributor.authorMaekawa, Hisatsuguen
dc.contributor.authorNishigori, Tatsutoen
dc.contributor.authorTsunoda, Shigeruen
dc.contributor.authorObama, Kazutakaen
dc.contributor.authorMiyoshi, Hiroyukien
dc.contributor.authorShimono, Yoheien
dc.contributor.authorMark Taketo, M.en
dc.contributor.authorSakai, Yoshiharuen
dc.contributor.alternative久森, 重夫ja
dc.contributor.alternative福山, 啓太ja
dc.contributor.alternative板谷, 喜朗ja
dc.contributor.alternative錦織, 達人ja
dc.contributor.alternative角田, 茂ja
dc.contributor.alternative小濵, 和貴ja
dc.contributor.alternative三好, 弘之ja
dc.contributor.alternative武藤, 誠ja
dc.contributor.alternative坂井, 義治ja
dc.date.accessioned2020-05-26T01:46:24Z-
dc.date.available2020-05-26T01:46:24Z-
dc.date.issued2019-12-01-
dc.identifier.issn2072-6694-
dc.identifier.urihttp://hdl.handle.net/2433/250985-
dc.description.abstractA lack of caudal-type homeobox transcription factor 2 (CDX2) protein expression has been proposed as a prognostic biomarker for colorectal cancer (CRC). However, the relationship between CDX2 levels and the survival of patients with stage II/III CRC along with the relationship between microRNAs (miRs) and CDX2 expression are unclear. Tissue samples were collected from patients with stage II/III CRC surgically treated at Kyoto University Hospital. CDX2 expression was semi-quantitatively evaluated by immunohistochemistry (IHC). The prognostic impacts of CDX2 expression on overall survival (OS) and relapse-free survival (RFS) were evaluated by multivariable statistical analysis. The expression of miRs regulating CDX2 expression and their prognostic impacts were analyzed using The Cancer Genome Atlas Program for CRC (TCGA-CRC). Eleven of 174 CRC tissues lacked CDX2 expression. The five-year OS and RFS rates of patients with CDX2-negative CRC were significantly lower than those of CDX2-positive patients. Multivariate analysis of clinicopathological features revealed that CDX2-negative status is an independent marker of poor prognosis in stage II/III CRC. miR-9-5p was shown to regulate CDX2 expression. TCGA-CRC analysis showed that high miR-9-5p expression was significantly associated with poor patient prognosis in stage II/III CRC. In conclusion, CDX2, the post-transcriptional target of microRNA-9-5p, is a useful prognostic biomarker in patients with stage II/III CRC.en
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI AGen
dc.rights© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).en
dc.subjectCDX2en
dc.subjectstage II/III colorectal canceren
dc.subjectmicroRNA-9-5pen
dc.titleMicrorna-9-5p-CDX2 axis: A useful prognostic biomarker for patients with stage II/III colorectal canceren
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleCancersen
dc.identifier.volume11-
dc.identifier.issue12-
dc.relation.doi10.3390/cancers11121891-
dc.textversionpublisher-
dc.identifier.artnum1891-
dc.addressDepartment of Surgery, Graduate School of Medicine, Kyoto Universityen
dc.addressDepartment of Surgery, Graduate School of Medicine, Kyoto Universityen
dc.addressDepartment of Surgery, Graduate School of Medicine, Kyoto University・Department of Gastroenterological Surgery, Osaka Red Cross Hospitalen
dc.addressDepartment of Clinical Oncology, Kyoto University Hospitalen
dc.addressDepartment of Surgery, Graduate School of Medicine, Kyoto Universityen
dc.addressDepartment of Surgery, Graduate School of Medicine, Kyoto Universityen
dc.addressDepartment of Surgery, Graduate School of Medicine, Kyoto Universityen
dc.addressDepartment of Surgery, Graduate School of Medicine, Kyoto Universityen
dc.addressDepartment of Surgery, Graduate School of Medicine, Kyoto Universityen
dc.addressDepartment of Surgery, Graduate School of Medicine, Kyoto Universityen
dc.addressDepartment of Surgery, Graduate School of Medicine, Kyoto Universityen
dc.addressDivision of Experimental Therapeutics, Department of Gastrointestinal Surgery, Graduate School of Medicine, Kyoto Universityen
dc.addressDepartment of Biochemistry, School of Medicine, Fujita Health Universityen
dc.addressDivision of Experimental Therapeutics, Graduate School of Medicine, Kyoto Universityen
dc.addressDepartment of Surgery, Graduate School of Medicine, Kyoto Universityen
dc.identifier.pmid31783700-
dcterms.accessRightsopen access-
datacite.awardNumber16K10539
jpcoar.funderName日本学術振興会ja
jpcoar.funderName.alternativeJapan Society for the Promotion of Science (JSPS)en
Appears in Collections:Journal Articles

Show simple item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.